Tafamidis is entering the clinical arena for the treatment of transthyretinârelated cardiomyopathy: certainties and unmet needs
Authors: Claudio Rapezzi, Alberto Aimo, Michele Emdin
Published: 2021-01-15
DOI:
10.1002/ejhf.2104
Source:
Full article
Abstract
No abstract found.